Table 1 Demographics at baseline
Characteristic | All (n = 42) | Anti-IL-5 therapy responder (n = 32) | Anti-IL-5 therapy non-responder (n = 10) | p-value | |||
|---|---|---|---|---|---|---|---|
Age (years), median (IQR) | 51 | (45–59) | 51 | (44–60) | 50 | (44–58) | 0.456 |
Female, n (%) | 19 | (45) | 16 | (50) | 3 | (30) | 0.267 |
Allergies, n (%) | 24 | (57) | 17 | (53) | 7 | (70) | 0.347 |
Smoking history, n (%) | |||||||
active smoker | 1 | (2) | 1 | (3) | 0 | (0) | |
ex-smoker | 20 | (48) | 14 | (44) | 6 | (60) | |
non-smoker | 21 | (50) | 17 | (53) | 4 | (40) | 0.432 |
Pack years, median (IQR) | 20 | (10–33) | 15 | (7–35) | 20 | (10–20) | 0.708 |
Body mass index, median (IQR) | 28 | (24–34) | 28 | (24–31) | 31 | (27–36) | 0.078 |
Lung function, median (IQR) | |||||||
FEV1% of predicted | 56 | (41–71) | 55 | (46–67) | 69 | (39–80) | 0.635 |
FEV1 (l) | 1.8 | (1.4–2.4) | 1.8 | (1.3–2.3) | 1.8 | (1.5–2.7) | 0.322 |
FVCex % of predicted | 82 | (72–98) | 78 (71–93) | 94 ( | 82–101) | 0.108 | |
RV % of predicted | 136 | (119–174) | 139 | (122–174) | 122 | (107–162) | 0.419 |
TLC % of predicted | 100 | (95–110) | 101 | (94–111) | 98 | (93–107) | 0.737 |
Laboratory, median (IQR) | |||||||
Blood eosinophils (%) | 7 | (5–10) | 7 | (5–10) | 6 | (4–12) | 0.589 |
Eosinophils absolute (cells/μl) | 0.6 | (0.4–0.8) | 0.6 | (0.4–0.8) | 0.5 | (0.4–1.0) | 0.228 |
IgE (IE/ml) | 128 | (77–1222) | 123 | (66–1487) | 298 | (84–1362) | 0.966 |
Continuous OCS therapy prior to IL-5 therapy, n (%) | 23 | (57) | 17 | (53) | 6 | (60) | 0.703 |
Number of exacerbations per year prior to anti-IL-5 therapy, mean (±SD) | 1.60 | (±1.70) | 1.78 | (±1.77) | 1.0 | (±1.33) | 0.208 |